LOS ANGELES, July 17 — A new wave of cancer treatment is quietly taking shape, one that turns away from the blunt force of traditional chemotherapy and toward the subtle vulnerabilities hidden inside a tumor’s own metabolism. The shift is laid out in a 2025 review published in Trends in Pharmacological Sciences, the work of researchers at Trethera and UCLA. They focus on a single enzyme: deoxycytidine kinase, or dCK.
Unlike the broad, punishing sweep of conventional chemo, which dates back to the 1940s and drugs like nitrogen mustard, this approach aims to hit a metabolic weak point that cancer cells cannot easily hide. Standard chemotherapy targets all rapidly dividing cells.
That is why it works — and why it causes such collateral damage to healthy tissue. The dCK approach is different. The enzyme is overexpressed in several specific cancers: acute lymphoblastic leukemia, non-small cell lung cancer, and pancreatic cancer.
That overexpression makes it a selective target, a kind of biochemical bullseye that normal cells largely lack. Trethera’s candidate drug, TRE-515, is designed to exploit that vulnerability.
It is a dCK inhibitor, meaning it blocks the enzyme’s activity in cancer cells. The science draws on a deep well of research into cancer metabolism, reaching back to Otto Warburg’s 1920s observation of altered glucose metabolism in cancer. For decades, that insight — the Warburg effect — remained more a curiosity than a clinical tool.
Now, it is becoming the foundation for a generation of therapies that treat cancer not just as a disease of runaway growth, but as a metabolic disorder. The review notes that dCK is particularly active in the three cancers mentioned — ALL, lung cancer, and pancreatic cancer — all of which have historically been difficult to treat with standard approaches. Pancreatic cancer, in particular, has long frustrated oncologists with its resistance to chemotherapy.
What this means for patients is still unfolding. TRE-515 is in development, and the research is early.
But the logic is compelling: instead of poisoning every fast-growing cell in the body, target the specific metabolic engine that powers the tumor. The Trethera and UCLA team published their findings in 2025, laying out the case for dCK as a viable target. The work builds on decades of metabolic research, but it also represents a deliberate pivot — away from the one-size-fits-all toxicity of older drugs and toward a more precise, biology-driven strategy.
The review does not promise a cure. It describes a path.
And for the families waiting on better options for hard-to-treat cancers, that path is worth watching. Consult your doctor for medical advice.
Sources
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Cancer Care Shift: From Chemotherapy to Precision Metabolism”, “description”: “LOS ANGELES, July 17 — A new wave of cancer treatment is quietly taking shape, one that turns away from the blunt force of traditional…”, “datePublished”: “2026-07-17T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “James Roberto”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}, “citation”: [{“@type”: “CreativeWork”, “url”: “https://en.wikipedia.org/wiki/Cancer_therapy”}]}
